| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | EVP of Research & Development
2 companies
Alvin Shih is EVP of Research & Development at TVTX and has filed Form 4s across 2 companies. Alvin Shih's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $8.0M at current prices.
The biggest single holding is TVTX (~$7.8M) as EVP of Research & Development. The TVTX filings lean toward selling, a net 71,666 shares.
Alvin Shih has 13 Form 4 filings on record from June 2015 to June 2026, across 2 companies: Director at Zevra Therapeutics (ZVRA), 2024–2026; EVP of Research & Development at Travere Therapeutics (TVTX), 2015–2016.
The 15 reported transactions were 8 open-market sales, 6 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $158K and 6 sales worth about $1.7M.
The only open-market purchase was 20,000 shares of ZVRA at an average $7.89 on September 12, 2025, about $158K. Twelve months later ZVRA was up 55%.
The largest open-market sale was 27,916 shares of TVTX at an average $32.70 on June 26, 2015, about $913K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 12, 2025 | ZVRA Zevra Therapeutics, Inc. | Director | Buy | 20,000 | $7.89 | $157,800.00 | New | +8.3% | +55.0% | |
| Sep 1, 2016 | TVTX Travere Therapeutics, Inc. | EVP of Research & Development | Sell | 8,750 | $16.24 | $142,058.88 | -5.2% | - | - | |
| Jun 1, 2016 | TVTX Travere Therapeutics, Inc. | EVP of Research & Development | Sell | 8,750 | $17.75 | $155,283.63 | -5.0% | - | - | |
| Mar 1, 2016 | TVTX Travere Therapeutics, Inc. | EVP of Research & Development | Sell | 8,750 | $14.35 | $125,568.63 | -4.7% | - | - | |
| Dec 9, 2015 | TVTX Travere Therapeutics, Inc. | EVP of Research & Development | Sell | 8,750 | $20.83 | $182,262.50 | -4.5% | - | - | |
| Oct 6, 2015 | TVTX Travere Therapeutics, Inc. | EVP of Research & Development | Sell | 8,750 | $20.12 | $176,072.88 | -4.3% | - | - | |
| Jun 26, 2015 | TVTX Travere Therapeutics, Inc. | EVP of Research & Development | Sell | 27,916 | $32.70 | $912,850.41 | -12.1% | - | - |